Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
Metrics to compare | INIT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINITPeersSector | |
---|---|---|---|---|
P/E Ratio | −14.7x | −3.6x | −0.5x | |
PEG Ratio | −0.38 | −0.05 | 0.00 | |
Price/Book | 13.9x | 1.2x | 2.6x | |
Price / LTM Sales | - | 6.5x | 3.1x | |
Upside (Analyst Target) | 264.8% | 644.3% | 45.7% | |
Fair Value Upside | Unlock | 10.3% | 5.7% | Unlock |